Global Particle Therapy System Market - 2022-2029

Market Overview

Particle Therapy System Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.6% during the forecast period (2022-2029).

Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. Proton Therapy System provides cancer therapy via pencil beam spot scanning technology. Particle therapy could minimize the extent and severity of normal tissue injury. Particle therapy is one of the cutting-edge areas of external beam radiotherapy. Growth in the particle therapy market is primarily driven by factors such as the several advantages offered by particle therapy over photon therapy, the growing prevalence of cancer, the increasing adoption of particle therapy in clinical trials, and the rising number of particle therapy centers worldwide.

Market Dynamics: Rising number of cancer cases globally drives particle therapy systems market.

According to the National Cancer Institute, in 2020, an estimated 1.8 million new cancer cases will be diagnosed in the US, and 606,520 mortalities will be registered from the disease. In 2020, prostate, colorectal, and lung cancers accounted for around 43.0% of all cancers diagnosed in men. For women, the three most common cancers are lung, breast, and colorectal, accounting for around 50% of all new cancer diagnoses in women. With the rising cancer cases, the demand for therapy systems will increase, offering growth opportunities to the particle therapy system market during the forecast period.

Moreover, increasing consumers' awareness of particle therapy systems drives the market growth. Also, the advantages of proton therapy over conventional radiotherapy divert patients towards proton therapy. Several types of research have stated that proton therapy can cause short- and long-term side effects compared to standard radiation therapy, which includes reducing the chances of secondary tumors occurrence and improving quality of life. Therefore, the transition from conventional therapy to proton therapy is increasing globally.

Market Segmentation: The treatment segment accounted for the highest share in global particle therapy system market.

Based on the application, the particle therapy system market has been classified into treatment and research applications.

The treatment application segment dominated the total market in 2019. This dominance is backed by its growing use in discovery, manufacturing, and drug development. Moreover, the rising adoption of particle therapy systems in various cancer diagnoses, including immune system diseases, bone marrow diseases, and other infectious diseases, are driving the market.

Based on the type, the particle therapy system market has been classified into proton therapy systems and heavy ion therapy.

The proton therapy segment dominated the global particle therapy system market in the forecast period, backed by several advantageous factors, such as the high degree of precision, reduced side effects associated with proton therapy, and shorter treatment time. These factors are accelerating the growth of the proton therapy market, a transition from heavy ion therapy.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the particle therapy system market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America dominates the global particle therapy system market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American multiplex assay market in 2022. The market is mainly driven by the presence of well-developed technologically advanced healthcare infrastructure in the US coupled with increased funding by government agencies.

Moreover, Asia Pacific is projected to grow at the fastest CAGR in the particle therapy system market during the forecast period. China is estimated to dominate the Asia Pacific market due to the increase in patient population, rapidly developing healthcare infrastructure and significant rise in R&D activities in pharmaceutical companies in the region.

Competitive Landscape:

The particle therapy system market is highly competitive, owing to the large presence of particle therapy system brands. The key particle therapy system players include Danfysik A/S, Advanced Oncotherapy PLC, Hitachi, Ltd., Optivus Proton Therapy, Inc., Mevion Medical Systems, Inc., Provision Healthcare, LLC, Protom International, Inc., Ion Beam Applications Sa (IBA), Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc., HD Biosciences Co., Ltd. The crucial players are adopting new Product & Service launches and expansion strategies for global growth in the particle therapy system market. In June 2021, Advanced Oncotherapy signed a deal to provide three LIGHT system treatment rooms for US$107mln. This contract value is used for the purchase of light equipment, installation and long-term maintenance and warranty agreement. This system is installed in a proton therapy center in Switzerland. August 2022, Mevion Medical Systems, a leading manufacturer and supplier of proton particle therapy for the treatment of cancer patients delivered the MEVION S250i Proton therapy system to Tongji Hospital of Tongji Medical College, China. Proton therapy is superior to radiation therapy; that can reduce the unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. The adoption of particle therapy is increasing due to the adoption of proton particle therapy to reduce harmful radiation.

COVID-19 Impact: Negative impact on the global particle therapy system market.

The COVID-19 pandemic is estimated to derail the particle therapy system market growth during the forecast period. The market has seen a modest decrease in 2020, backed by the decline in its adoption while developing vaccines for COVID-19. Governments have provided guidelines for elective surgeries to reduce the strain on the healthcare system, decrease disease transmission, and conserve personal protective equipment. Therefore, a modest downfall was witnessed by the particle therapy system market in 2020. The global cancer burden increased by 20% during the pandemic. It can be attributed to the postponement of diagnosis and treatment procedures. Particle therapy emergency services were available in almost all cancer treatment centers, and the number of patients visiting centers for treatment has reduced during the pandemic. Closed manufacturing facilities due to lockdowns have disrupted supply chains, and reduced recruitments for clinical trials negatively impacted the growth of the overall particle therapy devices market in the Covid Pandemic.

The global particle therapy system market report would provide an access to approximately 77 market data tables, 71 figures and 170 pages